JZYY(SH:600750)2025-04-25 11:00Financial Performance - The company's operating revenue for Q1 2025 was ¥1,184,099,207.93, a decrease of 7.03% compared to ¥1,227,404,483.82 in the same period last year[5] - Net profit attributable to shareholders was ¥284,914,263.90, representing an increase of 5.91% from ¥266,779,517.36 year-on-year[5] - Basic and diluted earnings per share were both ¥0.45, up 4.65% from ¥0.43 in the same period last year[6] - Net profit for Q1 2025 reached approximately ¥306.70 million, an increase of 6% from ¥288.94 million in Q1 2024[22] - Total operating revenue for Q1 2025 was approximately ¥1.18 billion, a decrease of 7% compared to ¥1.27 billion in Q1 2024[20] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 126.35%, reaching ¥176,743,360.23 compared to ¥82,585,412.66 in the previous year[5] - Cash flow from operating activities for Q1 2025 was approximately ¥176.74 million, significantly up from ¥78.08 million in Q1 2024[23] - Cash and cash equivalents rose to ¥1,620,163,496.21 from ¥1,007,379,500.74, an increase of about 60.8%[16] - Cash and cash equivalents at the end of Q1 2025 totaled approximately ¥699.03 million, an increase from ¥656.91 million at the end of Q1 2024[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,684,470,897.63, reflecting a 2.71% increase from ¥6,527,119,870.40 at the end of the previous year[6] - Total current assets increased to ¥3,214,156,416.55 from ¥2,487,609,574.79, representing a growth of approximately 29.3%[17] - Total liabilities decreased to ¥1,905,663,636.33 from ¥2,036,298,092.84, a reduction of approximately 6.4%[18] - The company’s total liabilities and equity amounted to approximately ¥6.68 billion as of the end of Q1 2025, compared to ¥6.51 billion at the end of Q1 2024[19] Revenue Breakdown - Revenue from prescription drugs increased by 23.68% to ¥187,301,915.91, with a gross profit margin of 49.29%[12] - Revenue from non-prescription drugs decreased by 12.12% to ¥885,359,526.13, with a gross profit margin of 76.14%[12] - The gross profit margin for the pharmaceutical industry segment was 68.24%, an increase of 1.12 percentage points compared to the previous year[12] Shareholder Information - Total number of common shareholders at the end of the reporting period is 38,567[14] - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds 272,010,336 shares, accounting for 43.24% of total shares[14] Other Financial Metrics - The company reported a total of ¥23,738,165.88 in non-recurring gains and losses for the period[9] - The company reported a significant increase in other income, totaling approximately ¥33.07 million in Q1 2025, compared to ¥4.20 million in Q1 2024[20] - The company experienced a decrease in sales expenses, which were approximately ¥400.26 million in Q1 2025, down from ¥453.36 million in Q1 2024[20] Changes and Developments - The company acquired 51% of Jiangxi Jiangzhong Traditional Chinese Medicine Co., Ltd. in December 2024, leading to retrospective adjustments in financial data[7] - The company has no significant changes in the shareholding structure or participation in margin trading activities[15] - The company reported no new strategies or significant developments in product or technology during the reporting period[15] - The new accounting standards or interpretations will be first implemented starting from 2025, affecting the financial statements at the beginning of the year[25]